Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
10:00am, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to
What's Going On With Replimune Stock On Tuesday?
01:44pm, Tuesday, 05'th May 2026
U.S. Food and Drug Administration (FDA) Commissioner Marty Makary defended his leadership in a CNBC interview aired Tuesday, growing criticism with concerns centering on drug approval decisions and in
FDA Commissioner Makary defends agency's decision on Replimune's drug
10:58am, Tuesday, 05'th May 2026
U.S. Food and Drug Administration Commissioner Dr. Marty Makary on Tuesday defended the agency's decision to not approve Replimune's drug for advanced skin cancer.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
09:42pm, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
05:25pm, Tuesday, 28'th Apr 2026
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investo
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
12:56pm, Wednesday, 22'nd Apr 2026
Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had nothing to do with the U.S. FDA's decision to not approve Replimune's drug for advanced skin cancer, saying
FDA Rejection Sparks Questions On Replimune Drug Approval Path
01:44pm, Monday, 13'th Apr 2026
Replimune Group Inc. (NASDAQ: REPL) on Friday received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application.
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
12:35pm, Monday, 13'th Apr 2026
REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.
Replimune melanoma therapy rejected by FDA, shares plunge
11:46am, Monday, 13'th Apr 2026
Replimune Group (NASDAQ:REPL) shares fell roughly 63% following the company's disclosure that it received a Complete Response Letter (CRL) from the US Food and Drug Administration, effectively blocki
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'
11:46am, Monday, 13'th Apr 2026
Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street' to discuss the company's next steps after the FDA denied its melanoma drug.
Stock Market Today (LIVE): Futures Rebound as Investors Shift Focus to Bank Earnings Despite U.S. Navy Blockade and Rising Crude
09:42am, Monday, 13'th Apr 2026
Top insights from the latest market news from Monday, April 13, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno
US FDA declines to approve Replimune's drug for advanced skin cancer
11:24am, Friday, 10'th Apr 2026
The U.S. Food and Drug Administration on Friday declined to approve Replimune's drug for advanced skin cancer, the regulator said.
Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares of Stock
04:59am, Tuesday, 07'th Apr 2026
Replimune Group, Inc. (NASDAQ: REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the business's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Hold” by Analysts
04:32am, Friday, 27'th Mar 2026
Replimune Group, Inc. (NASDAQ: REPL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two a
